Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
